240 related articles for article (PubMed ID: 34721552)
1. The Predictive Role of Immune Related Subgroup Classification in Immune Checkpoint Blockade Therapy for Lung Adenocarcinoma.
Yu X; Wang Z; Chen Y; Yin G; Liu J; Chen W; Zhu L; Xu W; Li X
Front Genet; 2021; 12():771830. PubMed ID: 34721552
[No Abstract] [Full Text] [Related]
2. A bioinformatics-based immune-related prognostic index for lung adenocarcinoma that predicts patient response to immunotherapy and common treatments.
Wang C; Lu T; Xu R; Chang X; Luo S; Peng B; Wang J; Yao L; Wang K; Shen Z; Zhao J; Zhang L
J Thorac Dis; 2022 Jun; 14(6):2131-2146. PubMed ID: 35813746
[TBL] [Abstract][Full Text] [Related]
3. Prognostic model incorporating immune checkpoint genes to predict the immunotherapy efficacy for lung adenocarcinoma: a cohort study integrating machine learning algorithms.
Yang XL; Zeng Z; Wang C; Wang GY; Zhang FQ
Immunol Res; 2024 May; ():. PubMed ID: 38755433
[TBL] [Abstract][Full Text] [Related]
4. Analysis of immune-related signatures of lung adenocarcinoma identified two distinct subtypes: implications for immune checkpoint blockade therapy.
Wang Q; Li M; Yang M; Yang Y; Song F; Zhang W; Li X; Chen K
Aging (Albany NY); 2020 Feb; 12(4):3312-3339. PubMed ID: 32091408
[TBL] [Abstract][Full Text] [Related]
5. A Novel Immune-Prognosis Index Predicts the Benefit of Lung Adenocarcinoma Patients.
Bai Y; Pei Y; Xia L; Ma L; Deng S
Front Pharmacol; 2022; 13():818170. PubMed ID: 35614936
[No Abstract] [Full Text] [Related]
6. Clinical Significance and Immunometabolism Landscapes of a Novel Recurrence-Associated Lipid Metabolism Signature In Early-Stage Lung Adenocarcinoma: A Comprehensive Analysis.
Zhu M; Zeng Q; Fan T; Lei Y; Wang F; Zheng S; Wang X; Zeng H; Tan F; Sun N; Xue Q; He J
Front Immunol; 2022; 13():783495. PubMed ID: 35222371
[TBL] [Abstract][Full Text] [Related]
7. Development and Validation of a Combined Hypoxia and Immune Prognostic Classifier for Lung Adenocarcinoma.
Huang H; Zhu G; Shi R; Li Y; Zhang Z; Xu S; Chen C; Cao P; Pan Z; Zhang H; Liu M; Liu H; Chen J
J Cancer; 2022; 13(8):2631-2643. PubMed ID: 35711827
[TBL] [Abstract][Full Text] [Related]
8. Development and Validation of a Ferroptosis-Related Gene Signature for Overall Survival Prediction in Lung Adenocarcinoma.
Tian Q; Zhou Y; Zhu L; Gao H; Yang J
Front Cell Dev Biol; 2021; 9():684259. PubMed ID: 34307361
[No Abstract] [Full Text] [Related]
9. Development and Validation of a Prognostic Index Based on Genes Participating in Autophagy in Patients With Lung Adenocarcinoma.
Wu ZX; Huang X; Cai MJ; Huang PD; Guan Z
Front Oncol; 2021; 11():799759. PubMed ID: 35145906
[TBL] [Abstract][Full Text] [Related]
10. Development and validation of an immune-related prognostic signature in lung adenocarcinoma.
Sun S; Guo W; Wang Z; Wang X; Zhang G; Zhang H; Li R; Gao Y; Qiu B; Tan F; Gao Y; Xue Q; Gao S; He J
Cancer Med; 2020 Aug; 9(16):5960-5975. PubMed ID: 32592319
[TBL] [Abstract][Full Text] [Related]
11. Deep neural network classification based on somatic mutations potentially predicts clinical benefit of immune checkpoint blockade in lung adenocarcinoma.
Peng J; Zou D; Gong W; Kang S; Han L
Oncoimmunology; 2020; 9(1):1734156. PubMed ID: 32158626
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive analysis of resistance mechanisms to EGFR-TKIs and establishment and validation of prognostic model.
Yang Z; Li H; Dong T; Li G; Chen D; Li S; Wang Y; Pan Y; Lu T; Yang G; Zhang G; Cheng P; Wang X
J Cancer Res Clin Oncol; 2023 Nov; 149(15):13773-13792. PubMed ID: 37532906
[TBL] [Abstract][Full Text] [Related]
13. Glycolysis Define Two Prognostic Subgroups of Lung Adenocarcinoma With Different Mutation Characteristics and Immune Infiltration Signatures.
Huo C; Zhang MY; Li R; Liu TT; Li JP; Qu YQ
Front Cell Dev Biol; 2021; 9():645482. PubMed ID: 34368114
[TBL] [Abstract][Full Text] [Related]
14. Transcriptome analysis of adipocytokines and their-related LncRNAs in lung adenocarcinoma revealing the association with prognosis, immune infiltration, and metabolic characteristics.
Ren J; Zhang H; Wang J; Xu Y; Zhao L; Yuan Q
Adipocyte; 2022 Dec; 11(1):250-265. PubMed ID: 35410586
[TBL] [Abstract][Full Text] [Related]
15. Development and validation of a robust immune-related prognostic signature in early-stage lung adenocarcinoma.
Wu P; Zheng Y; Wang Y; Wang Y; Liang N
J Transl Med; 2020 Oct; 18(1):380. PubMed ID: 33028329
[TBL] [Abstract][Full Text] [Related]
16. Identification and Validation of a Novel Immune-Related Four-lncRNA Signature for Lung Adenocarcinoma.
Wang J; Yin X; Zhang YQ; Ji X
Front Genet; 2021; 12():639254. PubMed ID: 33708243
[TBL] [Abstract][Full Text] [Related]
17. SPAG5 Expression Predicts Poor Prognosis and is Associated With Adverse Immune Infiltration in Lung Adenocarcinomas.
Xiao G; Xu X; Chen Z; Zeng J; Xie J
Clin Med Insights Oncol; 2023; 17():11795549231199915. PubMed ID: 37744424
[TBL] [Abstract][Full Text] [Related]
18. Integration of multiple key molecules in lung adenocarcinoma identifies prognostic and immunotherapeutic relevant gene signatures.
Wu Q; Wang L; Wei H; Li B; Yang J; Wang Z; Xu J; Zhou YL; Zhang B
Int Immunopharmacol; 2020 Jun; 83():106477. PubMed ID: 32278127
[TBL] [Abstract][Full Text] [Related]
19. Effect of TTN Mutations on Immune Microenvironment and Efficacy of Immunotherapy in Lung Adenocarcinoma Patients.
Wang Z; Wang C; Lin S; Yu X
Front Oncol; 2021; 11():725292. PubMed ID: 34513703
[TBL] [Abstract][Full Text] [Related]
20. A Seven-Gene Signature with Close Immune Correlation Was Identified for Survival Prediction of Lung Adenocarcinoma.
Zou X; Hu Z; Huang C; Chang J
Med Sci Monit; 2020 Jul; 26():e924269. PubMed ID: 32613949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
